ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AVCT Avacta Group Plc

47.75
-1.25 (-2.55%)
Last Updated: 09:51:38
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.25 -2.55% 47.75 47.50 48.00 48.75 47.50 48.75 1,217,445 09:51:38
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 10.06M -39.19M -0.1382 -3.46 135.43M
Avacta Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 49p. Over the last year, Avacta shares have traded in a share price range of 47.50p to 166.50p.

Avacta currently has 283,614,110 shares in issue. The market capitalisation of Avacta is £135.43 million. Avacta has a price to earnings ratio (PE ratio) of -3.46.

Avacta Share Discussion Threads

Showing 2976 to 2999 of 79650 messages
Chat Pages: Latest  126  125  124  123  122  121  120  119  118  117  116  115  Older
DateSubjectAuthorDiscuss
26/2/2018
19:11
In my opinion what do you expect they have been a total failure at every thing they have tried and expenses have rocketed every year. Shareholders expect to see a profit they have never ever made a profit even though the chairman forecast a profit 7 years ago.
poacher45
26/2/2018
18:49
The Market simply isn't attaching ANY value to any of the recent tie ups or scientific inflection points ... will it ever? and if so how much?

Depressing chart.

the drewster
23/2/2018
12:15
Who knows.
They keep going into jam tomorrow projects.

lantanatony
22/2/2018
21:57
How much cash have they got?
escapetohome
22/2/2018
21:48
If Avacta are a bargain.
Why are none of the big boys from the sector buying?
Is it thatthey don't believe the story?

lantanatony
16/2/2018
14:21
This is madness.
Someone sells 108 shares and it knocks 3% off the company's value.
Where is the broker support?!

lantanatony
15/2/2018
15:20
Simply no support from the broker!
Where is the bottom?

lantanatony
23/1/2018
10:45
Another small self founded deal.
But no big fish biting!

lantanatony
31/12/2017
10:28
I agree with Dec2000's points below but manufacturing to GMP standards is a whole new ball game from making small proteins for lab use. Assuming affimers can be made to meet the regulatory requirements for human trials, then the issue becomes how they can be differentiated from alternative for immuno-oncology trials. Like most small proteins, half-life can be extended by turning them into single-chain antibody-like proteins to extend half life by reducing renal clearance. Affimers could then be modified further to make them multimers to different binding sites. You then end up with something looking similar to bispecific single chain antibody but have made the manufacturing process more complex. However, the key issue is will these therapeutic proteins demonstrate improved properties over the competition that biotechgeek refers to? For example, will they show better penetration into solid tumours? Can they "pull" T-cells deeper into the tumour. Very exciting if they can but this will require a lot of cash to prove these theoretical benefits. Certainly worth watching this technology evolve to see how it will complete with the more established players.
derekj1
31/12/2017
10:27
I agree with Dec2000's points below but manufacturing to GMP standards is a whole new ball game from making small proteins for lab use. Assuming affimers can be made to meet the regulatory requirements for human trials, then the issue becomes how they can be differentiated from alternative for immuno-oncology trials. Like most small proteins, half-life can be extended by turning them into single-chain antibody-like proteins to extend half life by reducing renal clearance. Affimers could then be modified further to make them multimers to different binding sites. You then end up with something looking similar to bispecific single chain antibody but have made the manufacturing process more complex. However, the key issue is will these therapeutic proteins demonstrate improved properties over the competition that biotechgeek refers to? For example, will they show better penetration into solid tumours? Can they "pull" T-cells deeper into the tumour. Very exciting if they can but this will require a lot of cash to prove these theoretical benefits. Certainly worth watching this technology evolve to see how it will complete with the more established players.
derekj1
25/12/2017
08:12
Looking to invest in biotech and have enjoyed this thread. Typically for the sector, they have seem to have a technology that works but are struggling to commercialise it. Looks to early stage for me, as I like to see serious revenues coming in or at least the potential of them. Unusually, Avacta see to be holding back from even making "biodollars" forecasts. Looks like an early stage academic spinout that has become public too early. I'll keep looking though as there should be some good discounts at the next fundraise.
reester
11/12/2017
11:06
Firstly thanks to biotechgeek for his post which hopefully can start a good conversation. And of course his conclusion that the market will decide is also absolutely correct. He approaches the problem from the point of view of production.. and points out that the three main ways of producing affinity ligands are through synthetic chemistry, phage display and in vivo and goes on to point out that Avacta have “simply” made phage display work with a particular type of protein and they have chosen one that is particularly robust. In my belief this is accurate but also undersells what Avacta have achieved and what they are attempting to achieve. In my belief the production issue is not the most important concern.. what is of real significance is what Avacta are hoping to achieve through the use of this technology. The usefulness of any affinity ligand depends partly on the ligand and also what it is attached to and also what you are trying to use it for. In other words there are horses for courses. Indeed that is what Avacta have said : they are not interested in displacing the role of antibodies generally rather finding some alternatives which work better than antibodies in certain circumstances and they have effectively segmented their market into two : diagnostics and research reagents (the so called RxDx market) and the therapeutics market (the Tx market) . In the RxDx market there is massive competition but there are some advantages that Affimers can bring including ease of developing affinity ligands, small molecular size and stability as well as exquisite sensitivity. Of course they compete against phage-display produced antibodies and others, but they do have advantages themselves and other protein scaffolds have not entered the RxDx territory. The proof of this particular pudding does lie in the eating, but they are generating lots of sales leads and have indeed signed a deal with a top 3 diagnostics company… so it can’t be all bad! The question is - can they carve out for themselves a sensibly sized slice of this particular market? With regard to therapeutics, they have deliberately gone for a differentiated strategy which builds on the differences and advantages of Affimers which seems to me to be reasonable. They are using the ability of Affimers to link with themselves to make multimeric molecules which have significant potential uses as T cell recruiters and combination therapies (which might be more therapeutically effective and also more cost effective), they are using the stability of the cystatin molecule to develop drug conjugates with Glythera (also an IP company) which effectively add, say, a poison to the Affimer molecule to be able to selectively kill unwanted cells such as cancer cells; and they are using the simplicity of the cystatin protein and its ease of expression in cells in gene therapy approaches with Moderna. That sounds to me like a sensible approach and not to be denigrated. Whether it works or not of course is the question and why the shares are currently lowly rated. If any of the above are proved to work then the share price will be much higher. As biotechgeek says : the market will decide.
dec2000
10/12/2017
19:43
Tradernick is spot on and my point is that the likes of Finncap won't be able to raise the required capital.
The share price reflects that the market is not convinced.
Sadly the take up for Affimers so far has been disappointing and positive news flow in now critical.

lantanatony
10/12/2017
05:31
This is always the issue with biotechs: should they go for the more lucrative but much riskier therapeutic option or try and trade as a more conventional business. The problem is that on AIM is hard to be all things to different investors. Most successful companies on AIM, unlike NASDAQ, choose on or the other. This thread is a typical example of some investors who are expecting revenues and profits and others who want to cure cancer. This company is reaching out to both types of investor. For those who want to cure cancer, which is a noble objective, the key issue is will this particular approach work? I looks like there are literally thousands of competing immuno-oncology products in clinical development. A number of products are already on the market. By the time Avacta gets into the clinic, there will be even more. When you are in the clinic or the product is approved, it doesn't matter whether the product is an small molecule, antibody or affimer. It's the clinical data that counts - does it shrink the tumour or destroy it and stop it spreading? Many products can have effects on tumours in mice but it only with human clinical data that value will be recognised. Two years to phase 1 and then phase 2 and a lot of cash later you'll have your answer. The question is can you raise enough cash on AIM to get there? Most companies don't.
tradernick1
03/12/2017
07:21
Been reading this debate and thought I'd chip in. There are many different ways of making affinity ligands, the main ones are: synthetic chemistry (e.g. MIPs), phage display (e.g. Iontas)and in vivo (e.g. CRB). They all have their pros and cons and these basic methods can be combined in certain circumstances. Synthetic chemistry can make a much greater variety of compounds (most drugs and many diagnostics are made this way), as you are not limited by 23 the amino acids that make up proteins. Proteins can be made in bacteria or mammalian cells and this is more efficient that chemical synthesis. For example, human insulin for diabetics is made this way. Antibodies are just a type of protein that have a common backbone and are made in similar way to other proteins. Phage display can be used to make proteins, including antibodies, but the immune systems of animals only make antibodies. Most mammals make large antibodies but camels and lamas make smaller ones, as do sharks. All of these different technologies have been commercialised now. Animals can make antibodies to very small amounts of an impure antigen, whereas phage display typically requires larger amounts of pure protein. This can delay starting the phage display process, which is often why animals immune systems produce good results faster. Phage display was developed back in the 1990s and depends on what in available in the library and how many affinity maturation steps are required. It can be fast, it can be slow or it can fail all together. All Avacta have done is to get phage display to work with a particular type of protein, which is not hard. It seems that their man USP is that they are using a lysosomal protein as the starting point, which means it is more biochemically robust, as the lysosome is where proteins are degraded. To live there you have to be tough to survive! The downside for therapeutic applications is that lysomal proteins can be immunogenic in the human host, as they are rarely seen by the hosts immune system. So, "affimers", which is trademark, have their place in the market and the market will decide if they want to buy them in significant numbers. Looks like the jury is still out commercially: Avacta can make affimers but do others want to buy them at scale?
biotechgeek
01/12/2017
10:57
Looks like you won't have to wait long then.
lantanatony
01/12/2017
10:28
Im a buyer at 60
escapetohome
30/11/2017
12:54
At the current rate of decline Avacta will be around 60 pence next week.
Somewhat below the Finncap prediction of £2!
Meanwhile there have been a number of high profile presentations this year but no positive feedback from the company regarding these presentations
How did the Covance presentation
go for example?



Without any feedback,
No wonder the market has turned bearish on Avacta.

lantanatony
27/11/2017
15:14
Pugugly...In my opinion, potentially a serious competitor in terms of diagnostics and diagnostic reagents, but probably not from a therapeutic perspective. Recall, reagents were going to be a relatively easy win/gain early traction......

And absolutely no immune response is required and no animals are used in the manufacture of MIPs.

wan
27/11/2017
14:58
that's absolutely how I read it ... another alternative.

Gaining acceptance and traction may be impossible for ANY firm, as while they are standing still (relatively speaking) to do so, new tech becomes available or shows promise in a science lab somewhere.

the drewster
27/11/2017
13:51
wan: Thanks for that - If I read correctly could potentially provide very serious or superior competition to Avacta - or have I read wrongly ?
pugugly
27/11/2017
08:14
Something that I have been keeping an eye on -

21st November 2017

Breakthrough Discovery In Diagnostic Tools That Can Replace Antibodies

In a newly released article “A comparison of the performance of molecularly imprinted polymer nanoparticles for small molecule targets and antibodies in the ELISA format” the researchers successfully demonstrated that polymer nanoparticles produced by the molecular imprinting technique (MIP nanoparticles) can bind to the target molecule with the same or higher affinity and specificity than widely used commercially available antibodies and against challenging targets.

Additionally, their ease of manufacture, short lead time, high affinity and the lack of requirement for cold chain logistics make them an attractive alternative to traditional antibodies for use in immunoassays.

The robust nature of MIP nanoparticles makes them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing.

They can withstand harsh environments, such as extremes of pH and temperature, seawater and can even function in organic solvents.

Full article -

wan
20/11/2017
12:34
You paraphrase ... Alastair said if the events weren't supported, they'd obviously have to consider whether to run them in the future.

I think your negative view (of either the broker or the company) is entirely up to you, and that you express it means that it is quite possibly a view shared by others.

Everything helps to build a fuller picture.

PS - I don't think for one minute Avacta could "go it alone" on a therapeutic and will simply get to a compelling point before taking on a joint venture (the terms of which will define how golden the Goose's eggs actually are)

the drewster
20/11/2017
11:48
Here is a fact for you ,when FinnCap were appointed Avacta were around a £1 !
Here's another one Mr Smith told The Drewster that these private shareholder events may be a waist of time before my posting!
I am not surprised FinnCap are backtracking about their involvement in the event.
It is still my view that neither FinnCap and or Avacta did enough to get people to the event to promote the company.
Therapeutics is a big boy's game,therefore in my opinion that requires a big boy's Broker,that's prepared to support the shares.

lantanatony
Chat Pages: Latest  126  125  124  123  122  121  120  119  118  117  116  115  Older

Your Recent History

Delayed Upgrade Clock